RPR vs FTA-ABS: Syphilis Blood Tests Explained

RPR and FTA-ABS are two blood tests that work together to diagnose syphilis. The RPR is a nontreponemal screening test that detects the body's general reaction to infection and falls with treatment. The FTA-ABS is a treponemal confirmatory test that detects antibodies to the syphilis bacterium itself and usually stays positive for life. You need both.

The two-step logic: a nontreponemal screen plus a treponemal confirm

Syphilis is caused by the bacterium Treponema pallidum, and no single blood test diagnoses it cleanly on its own. That's because each test type makes a different trade-off. A screening test is built to catch everyone who might be infected: it's sensitive, but it occasionally flags people who aren't. A confirmatory test is built to rule out those false alarms, it's specific. Pairing the two is how syphilis serology guards against both a missed case and a wrong diagnosis.

This same belt-and-suspenders design shows up across serious infections: HIV and syphilis both use an initial screen followed by a different confirmatory test, and a result isn't final until the confirmatory step agrees CDC, HIV Testing. For syphilis, the screen and the confirm fall into two families, nontreponemal and treponemal, and understanding what each one actually measures is the whole game.

RPR / VDRL (nontreponemal): the screen that tracks treatment

The RPR (rapid plasma reagin) and the older VDRL detect antibodies your body makes against material released by damaged cells during infection, not against the bacterium directly. That indirectness is the point: it makes them cheap, fast, and easy to run in volume, which is why they're the front-line screen. A blood draw takes minutes, and most labs turn the result around in a day or a few CDC syphilis lab recs, 2024.

The other thing the RPR does that no treponemal test can: it reports a titer, a number like 1:8 or 1:64 that reflects how active the infection is. A high titer suggests active disease; after successful treatment, the titer falls over months. That makes the RPR the test clinicians watch to confirm a cure is working. Its weakness is the occasional false-positive: pregnancy, recent vaccines, other infections, and autoimmune conditions can all trigger a reactive RPR without syphilis present. That's exactly why it can't stand alone.

FTA-ABS / TP-PA (treponemal): the confirm that stays positive for life

The FTA-ABS (fluorescent treponemal antibody absorption) and TP-PA (T. pallidum particle agglutination) detect antibodies aimed directly at the syphilis bacterium. Because the target is the organism itself, these tests are far more specific, a positive treponemal test in a person with a reactive RPR is strong evidence of true infection.

There's a catch that confuses a lot of people: treponemal antibodies usually persist for life, even after the infection is cured. A treponemal test typically stays reactive forever, so it can't tell you whether an infection is current or was treated years ago, and it can't be used to track a cure. Treat it as a yes/no marker of "ever exposed," not a measure of disease activity.

Why both are needed: traditional vs reverse-sequence algorithms

Labs run the two tests in one of two orders, and which one your lab uses changes how your results read.

• Traditional algorithm: screen first with a nontreponemal test (RPR/VDRL), then confirm any reactive result with a treponemal test (FTA-ABS/TP-PA). This is the classic sequence and works well in higher-prevalence settings.
• Reverse-sequence algorithm: screen first with an automated treponemal test, then run an RPR on anyone who's reactive. This is common in modern high-volume labs because the treponemal step can be automated. When the treponemal screen is positive but the RPR is negative, a second, different treponemal test (like TP-PA) is used to sort it out.

Either way, the principle holds: a single reactive result is preliminary, and the diagnosis depends on agreement between a treponemal and a nontreponemal test, interpreted alongside your history and any symptoms.

What your results mean: reactive and nonreactive combinations

Here's how the common combinations typically read. Your clinician interprets these with your sexual history, exam, and any prior titers: this table is a map, not a self-diagnosis.

A nonreactive result soon after a possible exposure can be falsely reassuring, antibodies take time to develop. Testing too early is the main cause of a false negative: the test isn't wrong, the infection just isn't detectable yet, so a too-early negative should be repeated. If you're unsure about timing, see when to test after exposure and our explainer on STD test accuracy window period.

How results guide treatment and follow-up

Confirmed syphilis is treated with penicillin. For primary and secondary (early) syphilis in adults, the CDC recommends benzathine penicillin G 2.4 million units IM in a single dose CDC STI Guidelines, 2021. Late latent or unknown-duration syphilis is treated with three weekly IM doses, 7.2 million units total CDC, latent syphilis, and the AAFP summary of the same guidelines notes that neurosyphilis or ocular disease instead requires IV aqueous crystalline penicillin G for 10–14 days AAFP, 2021 guideline update. When penicillin can't be used, WHO suggests doxycycline 100 mg twice daily for 14 days, ceftriaxone 1 g IM daily for 10–14 days, or in special circumstances azithromycin 2 g once WHO treatment guideline; that same review estimated a single penicillin dose achieved serological cure in 840 per 1,000 people with early syphilis. Pregnant patients and infants follow specific regimens: congenital syphilis in infants can be treated with benzathine penicillin G 50,000 units/kg up to the adult dose CDC, congenital syphilis.

After treatment, the RPR, not the FTA-ABS, is how cure is confirmed. Your clinician repeats the nontreponemal titer over months and looks for it to fall. If it doesn't drop as expected, or it climbs again, that signals treatment failure or reinfection and prompts re-evaluation. This is the practical reason both test families matter: the treponemal test diagnoses, the nontreponemal test follows the response.

When to get tested and see a clinician

Many people with syphilis have no symptoms in the early stages, so testing, not how you feel, is what tells you your status. The USPSTF concluded with high certainty that screening nonpregnant people at increased risk has a substantial net benefit USPSTF, syphilis screening, and it gives an A recommendation to screen all pregnant people as early as possible USPSTF, pregnancy screening: a priority given that US congenital syphilis cases rose sharply in recent years, with 3,761 cases reported to the CDC in 2022 CDC MMWR, 2023. Globally, WHO estimated new adult syphilis cases climbed from 7.1 million in 2020 to 8.0 million in 2022 WHO, 2024, and a congenital case rate of 523 per 100,000 live births WHO dashboard.

See a clinician if you've had a possible exposure, a new partner, a sore or rash you can't explain, or if you're pregnant. Blood is drawn from your arm in minutes, the same visit can screen for other infections like chlamydia from a urine cup or swab USPSTF screening. You can get tested free or low-cost at health departments, Planned Parenthood, and Title X clinics; the US has about 15,000 community health center sites plus thousands of family-planning sites offering sliding-scale care HRSA health centers. At-home kits exist too, just mind the window period.

Want the wider view across all treponemal tests (TP-PA, EIA/CIA)? See RPR vs treponemal testing.

Keep exploring on EasySTD: which STD test you need, what STD testing costs and Syphilis testing.